GORAB

Across TCGA pan-cancer cohorts, GORAB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GORAB data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GORAB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GORAB expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GORAB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.435	0.866	.001	51	view →
PDAC	DFS	Quartile	All	0.574	0.234	.001	33	view →
LUAD	OS	Median	II,III,IV	1.000	0.867	.006	15	view →
LSCC	OS	Quartile	All	0.785	0.972	.025	7	view →
UCEC	OS	Median	All	0.964	0.862	.047	2	view →
HNSC	OS	Median	III,IV	0.484	1.000	.038	2	view →
GBM	DFS	Median	All	0.686	0.801	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GORAB–CCRCC (DFS)

Open the CCRCC breakdown →